Mizuho lowered the firm’s price target on Hologic to $85 from $95 and keeps a Buy rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOLX:
- Hologic partners with AAGL and Inovus Medical on OB-GYN training for EMIGS
- Hologic price target lowered to $77 from $81 at RBC Capital
- Hologic CEO: Our core business is stronger than ever
- Hologic elected Mohtashami to its board of directors
- Hologic, Bayer team to bring contrast-enhanced mammography package to facilities
